Nabriva raises $120m to take 'new class of antibiotic' into Phase III
This article was originally published in Scrip
Executive Summary
Nabriva Therapeutics, which is developing a new class antibiotics called pleuromutilins, has raised $120m in a series B financing involving a group of transatlantic investors. CEO Colin Broom told Scrip there was no key piece of data that secured the cash, but rather the "a package combining data from 450 treated patients" including a 200-patient Phase II efficacy trial.
You may also be interested in...
Nabriva Wants To Try A Different Approach To Antibiotic Stewardship
Nabriva sees an opportunity for its Phase III antibiotic lefamulin to be used as a first-line agent against community-acquired bacterial pneumonia, rather than being held in reserve, because it targets pathogens that cause lung infections.
venBio's $315m Pharma-Backed Fund Seeks Broad Range Of Investments
VenBio has $315m in new cash to invest in a broad array of therapeutics developers now that it has closed its second venture capital fund, which raised $65m more than the VC firm originally intended and reflects big pharma's increasing commitment to backing early-stage life science companies.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.